Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 187979, 14 pages
http://dx.doi.org/10.1155/2014/187979
Review Article

Chinese Patent Medicine Tongxinluo Capsule for Hypertension: A Systematic Review of Randomised Controlled Trials

Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange No. 5, Xicheng District, Beijing 100053, China

Received 4 November 2013; Accepted 31 December 2013; Published 17 February 2014

Academic Editor: Bo Feng

Copyright © 2014 Jie Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. C. Foster, A. M. Rawlings, E. Marrett et al., “Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States,” American Heart Journal, vol. 166, no. 1, pp. 150–156, 2013. View at Publisher · View at Google Scholar
  2. P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, and J. He, “Global burden of hypertension: analysis of worldwide data,” The Lancet, vol. 365, no. 9455, pp. 217–223, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. R. V. Picon, F. D. Fuchs, L. B. Moreira et al., “Trends in prevalence of hypertension in Brazil: a systematic review with meta-analysis,” Plos ONE, vol. 7, no. 10, pp. 1–6, 2012. View at Google Scholar
  4. B. V. Mittal and A. K. Singh, “Hypertension in the developing world: challenges and opportunities,” American Journal of Kidney Diseases, vol. 55, no. 3, pp. 590–598, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Yang, L. Kong, W. Zhao et al., “Emergence of chronic non-communicable diseases in China,” The Lancet, vol. 372, no. 9650, pp. 1697–1705, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Q. Ma, W. H. Mei, P. Yin et al., “Prevalence of hypertension in Chinese cities: a meta-analysis of published studies,” Plos ONE, vol. 8, no. 3, pp. 1–6, 2013. View at Google Scholar
  7. X. J. Xiong, X. C. Yang, W. Liu et al., “Trends in the treatment of hypertension from the perspective of traditional Chinese medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 275279, 13 pages, 2013. View at Publisher · View at Google Scholar
  8. G. J. Chen and M. S. Yang, “The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials,” Plos ONE, vol. 8, no. 3, Article ID e57854, pp. 1–6, 2013. View at Google Scholar
  9. X. J. Xiong, X. C. Yang, Y. M. Liu et al., “Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science,” Hypertension Research, vol. 36, pp. 570–579, 2013. View at Google Scholar
  10. H. Lee, S.-Y. Kim, J. Park, Y.-J. Kim, H. Lee, and H.-J. Park, “Acupuncture for lowering blood pressure: systematic review and meta-analysis,” American Journal of Hypertension, vol. 22, no. 1, pp. 122–128, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Wang and X. Xiong, “Control strategy on hypertension in Chinese medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 284847, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Zheng, H. Shi, J. Jia, D. Li, and S. Lin, “A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 12, no. 3, pp. 365–374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Wang and X. J. Xiong, “Evidence-based Chinese medicine for hypertension,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 978398, 12 pages, 2013. View at Publisher · View at Google Scholar
  14. N. Richard, “Complementary and alternative medicine approaches to blood pressure reduction,” Canadian Family Physician, vol. 54, pp. 1529–1533, 2008. View at Google Scholar
  15. J. Wang, P. Q. Wang, and X. J. Xiong, “Current situation and re-understanding of syndrome and formula syndrome in Chinese medicine,” Internal Medicine, vol. 2, Article ID 1000113, pp. 1–5, 2012. View at Google Scholar
  16. D. J. Su and L. F. Li, “Trends in the use of complementary and alternative medicine in the United States: 2002–2007,” Journal of Health Care for the Poor and Underserved, vol. 22, no. 1, pp. 296–310, 2011. View at Google Scholar · View at Scopus
  17. S. M. Ching, Z. A. Zakaria, F. Paimin et al., “Complementary alternative medicine use among patients with type 2 diabetes mellitus in the primary care setting: a cross-sectional study in Malaysia,” BMC Complementary and Alternative Medicine, vol. 13, article 148, 2013. View at Google Scholar
  18. H. Xu and K.-J. Chen, “Integrating traditional medicine with biomedicine towards a patient-centered healthcare system,” Chinese Journal of Integrative Medicine, vol. 17, no. 2, pp. 83–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Hawk, H. Ndetan, and M. W. Evans, “Potential role of complementary and alternative health care providers in chronic disease prevention and health promotion: an analysis of National Health Interview Survey data,” Preventive Medicine, vol. 54, no. 1, pp. 18–22, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Xu and K. J. Chen, “Complementary and alternative medicine: is it possible to be mainstream?” Chinese Journal of Integrative Medicine, vol. 18, pp. 403–404, 2012. View at Google Scholar
  21. X. J. Xiong, X. C. Yang, W. Liu et al., “Banxia baizhu tianma decoction for essential hypertension: a systematic review of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 271462, 10 pages, 2012. View at Publisher · View at Google Scholar
  22. R. Nahas, “Complementary and alternative medicine approaches to blood pressure reduction: an evidence-based review,” Canadian Family Physician, vol. 54, no. 11, pp. 1529–1533, 2008. View at Google Scholar · View at Scopus
  23. J. Wang, X. J. Xiong, and W. Liu, “Yoga for essential hypertension: a systematic review,” Plos ONE, vol. 8, no. 10, Article ID e76357, 6 pages, 2013. View at Google Scholar
  24. N. N. Shi, X. J. Han, W. Y. Yu et al., “Adoption in China of clinical practice guidelines for hypertension using traditional Chinese medical approaches: a literature review based on clinical studies,” The Journal of Alternative and Complementary Medicine, vol. 19, no. 1, pp. 1–8, 2013. View at Google Scholar
  25. J. Wang, X. J. Xiong, and W. Liu, “Acupuncture for essential hypertension,” International Journal of Cardiology, vol. 169, no. 5, pp. 317–326, 2013. View at Publisher · View at Google Scholar
  26. P. Benharash and W. Zhou, “Neuromodulation in treatment of hypertension by acupuncture: a neurophysiological prospective,” Health, vol. 5, no. 4, pp. 65–72, 2013. View at Google Scholar
  27. J.-I. Kim, J.-Y. Choi, H. Lee, M. S. Lee, and E. Ernst, “Moxibustion for hypertension: a systematic review,” BMC Cardiovascular Disorders, vol. 10, article 33, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. M. Ching, Z. A. Zakaria, F. Paimin et al., “ASSA13-14-17 effects of Tai Chi exercises on vascular function in middle-aged and elderly women with hypertension symptom,” Heart, vol. 99, supplement 1, p. A64, 2013. View at Google Scholar
  29. B. M. Y. Cheung, J. L. F. Lo, D. Y. T. Fong et al., “Randomised controlled trial of qigong in the treatment of mild essential hypertension,” Journal of Human Hypertension, vol. 19, no. 9, pp. 697–704, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. M. S. Lee, M. H. Pittler, R. Guo, and E. Ernst, “Qigong for hypertension: a systematic review of randomized clinical trials,” Journal of Hypertension, vol. 25, no. 8, pp. 1525–1532, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. J. X. Liu, X. H. Shang, and G. Wang, “Effect of tongxinluo capsule on experimental myocardial ischemia, arrhythmia and hyperlipidemia,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 17, no. 7, pp. 425–428, 1997. View at Google Scholar · View at Scopus
  32. Y.-T. Cheng, Y.-J. Yang, H.-T. Zhang et al., “Pretreatment with Tongxinluo protects porcine myocardium from ischaemia/reperfusion injury through a nitric oxide related mechanism,” Chinese Medical Journal, vol. 122, no. 13, pp. 1529–1538, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. G. C. Xu, R. L. Gao, and Y. L. Wu, “Clinical study on tongxinluo capsule in treatment of patients with angina pectoris caused by coronary heart disease,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 17, no. 7, pp. 414–416, 1997. View at Google Scholar · View at Scopus
  34. S.-J. You, Y.-J. Yang, K.-J. Chen et al., “The protective effects of Tong-xin-luo on myocardium and microvasculature after reperfusion in acute myocardial infarction,” Zhonghua Xin Xue Guan Bing Za Zhi, vol. 33, no. 5, pp. 433–437, 2005. View at Google Scholar · View at Scopus
  35. H.-T. Zhang, Z.-H. Jia, J. Zhang et al., “No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: a randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT trial),” Chinese Medical Journal, vol. 123, no. 20, pp. 2858–2864, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. P.-L. Bu, X.-Q. Zhao, L.-L. Wang, Y.-X. Zhao, C.-B. Li, and Y. Zhang, “Tong-xin-luo capsule inhibits left venticular remodeling in spontaneously hypertensive rats by enhancing PPAR-γ expression and suppressing NF-κB activity,” Chinese Medical Journal, vol. 121, no. 2, pp. 147–154, 2008. View at Google Scholar · View at Scopus
  37. C. Q. Zhang, L. Hong, and H. Wang, “Effects of tongxinluo capsule on platelet activating and inflammation factors as well as vascular endothelial function in patients with essential hypertension complicated with diabetes mellitus,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 30, no. 4, pp. 376–379, 2010. View at Google Scholar
  38. H. J. Wang, L. D. Xie, and E. H. Yao, “Effect of tongxinluo on myocardial fibrosis in Spontaneously Hypertensive Rats,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 1, pp. 189–190, 2003. View at Google Scholar
  39. J. Q. Liang, K. Wu, Z. H. Jia et al., “Chinese medicine Tongxinluo modulates vascular endothelial function by inducing eNOS expression via the PI-3K/Akt/HIF-dependent signaling pathway,” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 517–523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. J. P. T. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0, The Cochrane Collaboration, 2009.
  41. F. M. Liu and C. F. Liu, “Clinical observation on the treatment of essential hypertension by amlodipine in combination with tongxinluo capsule,” Journal of Community Medicine, vol. 7, no. 8, pp. 14–15, 2009. View at Google Scholar
  42. T. Li, S. Y. Wang, J. W. Hong et al., “The influence of tongxinluo on blood pressure and urinary albumin and the quality of life of the elderly hypertensives,” Journal of Integrated Traditional and Western Medicine of Cardia-Cerebrovascular Disease, vol. 1, no. 9, pp. 552–554, 2003. View at Google Scholar
  43. Y. G. Lu, C. H. Fu, H. Yan et al., “Influence of tongxinluo on blood endothelial microparticles in patients with hypertension,” Chinese Journal of Cardiovascular Rehabilitation Medicine, vol. 21, no. 6, pp. 654–657, 2012. View at Google Scholar
  44. Z. J. Xie, “The influence of tongxinluo on blood pressure of hypertension,” Journal of Bethune Military Medical College, vol. 4, no. 2, pp. 101–102, 2006. View at Google Scholar
  45. X. Wei and J. Y. Chen, “Influence of tongxinluo on carotid intima-media thickness (IMT) in patients with hypertension,” Chinese Journal of Difficult and Complicated Cases, vol. 8, no. 5, pp. 278–279, 2009. View at Google Scholar
  46. L. L. Xu, C. Y. Guan, C. Y. Wang et al., “Influence of tongxinluo on risk factors and target organ damage in patients with hypertension,” Chinese Journal of Basic Medicine in Traditional Chinese Medicine, vol. 15, no. 4, pp. 287–288, 2009. View at Google Scholar
  47. X. R. Zhao and W. B. Cheng, “The influence of tongxinluo capsule on left ventricular hypertrophy (LVH) and C-reactive protein (CRP) of senile primary hypertension patients,” Journal of the Jinhua Professional Technology Institute, vol. 10, no. 3, pp. 54–56, 2010. View at Google Scholar
  48. Z. Xu, L. Z. Wang, and Y. Hou, “Effects of tongxinluo capsule on the endothelial function in essential hypertension,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 5, no. 8, pp. 677–679, 2007. View at Google Scholar
  49. M. Zhu, “The curative effect of tongxinluo capsule on hypertension combined hyperuricemia,” Chinese and Foreign Medical Research, vol. 9, no. 14, p. 116, 2011. View at Google Scholar
  50. H. P. Rao, “Clinical efficacy of tongxinluo capsule in patients with essential hypertension and its effect on hemorheology,” Chinese Journal of Information on TCM, vol. 16, no. 12, pp. 15–17, 2009. View at Google Scholar
  51. Y. Q. Mo, S. J. Wu, and Q. Wang, “Clinical observation of tongxinluo capsule on hypertensive renal damage,” Chinese Journal of Difficult and Complicated Cases, vol. 8, no. 11, pp. 670–672, 2009. View at Google Scholar
  52. X. Y. Xu, “Clinical observation of amlodipine combined with tongxinluo capsule on essential hypertension,” Chinese Journal of Coal Industry Medicine, vol. 8, no. 5, pp. 480–482, 2005. View at Google Scholar
  53. Y. Y. Li, Y. W. Tong, and J. Hu, “The therapeutic alliance of tongxinluo capsule and conventional antihypertensive therapy on prevention of arteriosclerosis in elderly male patient with hypertension,” New Medicine, vol. 43, no. 11, pp. 768–771, 2012. View at Google Scholar
  54. W. J. Cheng, J. J. Xi, and Y. F. Niu, “Curative effect of tongxinluo combined with losartan on hypertension complicated with hyperuricemia,” China Tropical Medicine, vol. 11, no. 5, pp. 609–610, 2011. View at Google Scholar
  55. F. L. Wang, “Treating 97 cases of essential hypertension by Tongxinluo capsule plus Nifedipine retard,” Journal of Practical Traditional Chinese Internal Medicine, vol. 25, no. 5, pp. 78–79, 2011. View at Google Scholar
  56. J. F. Chen, H. C. Xu, and X. H. Chen, “Clinical observation of valsartan combined with tongxinluo in treatment of hypertension,” Chinese Journal of Modern Drug, vol. 5, no. 11, pp. 68–69, 2011. View at Google Scholar
  57. M. Liao, “The curative effect of tongxinluo capsule on hypertention with renal damage,” Practical Clinical Medicine, vol. 7, no. 2, pp. 19–27, 2006. View at Google Scholar
  58. Y. Zhang, “Research on the treatment of hypertensive renal damage by tongxinluo capsule,” Chinese Journal of Basic Medicine in Traditional Chinese Medicine, vol. 17, no. 8, pp. 897–898, 2011. View at Google Scholar
  59. J. Yan and Z. J. He, “Clinical observation of tongxinluo capsule combined with amlodipine in treatment of primary hypertension,” Hebei Medicine, vol. 13, no. 12, pp. 1222–1224, 2007. View at Google Scholar
  60. D. Jiang, “Treating 38 cases of hypertension with left ventricular hypertrophy by benazepril combined with tongxinluo capsule,” Henan Traditional Chinese Medicine, vol. 31, no. 10, pp. 1172–1173, 2011. View at Google Scholar
  61. H. L. Wang, D. X. Wei, and R. Y. Lin, “Clinical observation of Tongxinluo capsule combined with nifedipine sustained release tablets in the treatment of hypertension,” Chinese Journal of Clinical Healthcare, vol. 7, no. 6, pp. 425–426, 2004. View at Google Scholar
  62. Y. Lu and X. F. Zha, “Treating 40 cases of hypertension with hyperviscosity by tongxinluo capsule,” Journal of Practical Traditional Chinese Internal Medicine, vol. 19, no. 6, p. 580, 2005. View at Google Scholar
  63. J. L. Hu, “The clinical effect of enalapril combined with tongxinluo in treatment of hypertensive heart disease,” PJCCPVD, vol. 21, no. 6, pp. 93–94, 2013. View at Google Scholar
  64. Y. J. Lu and M. Zhou, “The effect of the treatment of heart rate variability of essential hypertension by tongxinluo capsule,” Prevention and Treatment of Cardio- Cerebra-L VascuLar Disease, vol. 7, no. 2, pp. 110–113, 2007. View at Google Scholar
  65. B. Zhao, Y. Y. Mao, Z. G. Hu et al., “Effect of the Tongxinluo capsule on primary hypertension,” Journal of Shandong University (Health Sciences), vol. 45, no. 8, pp. 855–857, 2007. View at Google Scholar
  66. J. Dou, “Effects of Tonx inluo on the left ven tr icular d ia stolic function in pa tien ts with hypertension and obesity,” Journal of Xinxiang Medical College, vol. 26, no. 1, pp. 80–82, 2009. View at Google Scholar
  67. Y. H. Wang, R. J. Li, S. H. Zhang et al., “Effect of tongxinluo capsules combined with valsartan on hypertrophy and function of left ventricle in treating hypertension,” Heibei Medicine, vol. 16, no. 10, pp. 1180–1182, 2010. View at Google Scholar
  68. L. L. Kjaergard, J. Villumsen, and C. Gluud, “Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses,” Annals of Internal Medicine, vol. 135, no. 11, pp. 982–989, 2001. View at Google Scholar · View at Scopus
  69. K. F. Schulz, L. Chalmers, R. J. Hayes, and D. G. Altman, “Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials,” Journal of the American Medical Association, vol. 273, no. 5, pp. 408–412, 1995. View at Publisher · View at Google Scholar · View at Scopus
  70. W. Zhou and J. C. Longhurst, “Review of trials examining the use of acupuncture to treat hypertension,” Future Cardiology, vol. 2, no. 3, pp. 287–292, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. E. Ernst and M. H. Pittler, “Alternative therapy bias,” Nature, vol. 385, no. 6616, p. 480, 1997. View at Google Scholar · View at Scopus
  72. M. H. Pittler, N. C. Abbot, E. F. Harkness, and E. Ernst, “Location bias in controlled clinical trials of complementary/alternative therapies,” Journal of Clinical Epidemiology, vol. 53, no. 5, pp. 485–489, 2000. View at Publisher · View at Google Scholar · View at Scopus
  73. N. Terrin, C. H. Schmid, and J. Lau, “In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias,” Journal of Clinical Epidemiology, vol. 58, no. 9, pp. 894–901, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. W. Wang, M. He, M. Zhou et al., “Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis,” Plos ONE, vol. 8, Article ID e84270, 2013. View at Google Scholar
  75. H. Xu and K.-J. Chen, “Herb-drug interaction: an emerging issue of integrative medicine,” Chinese Journal of Integrative Medicine, vol. 16, no. 3, pp. 195–196, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Skalli and R. Soulaymani Bencheikh, “Safety monitoring of herb-drug interactions: a component of pharmacovigilance,” Drug Safety, vol. 35, no. 10, pp. 785–791, 2012. View at Google Scholar
  77. D. Moher, S. Hopewell, K. F. Schulz et al., “CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials,” British Medical Journal, vol. 340, p. c869, 2010. View at Publisher · View at Google Scholar · View at Scopus